ES3012120T3 - Treatment of cholestatic pruritus with seladelpar - Google Patents

Treatment of cholestatic pruritus with seladelpar Download PDF

Info

Publication number
ES3012120T3
ES3012120T3 ES21201888T ES21201888T ES3012120T3 ES 3012120 T3 ES3012120 T3 ES 3012120T3 ES 21201888 T ES21201888 T ES 21201888T ES 21201888 T ES21201888 T ES 21201888T ES 3012120 T3 ES3012120 T3 ES 3012120T3
Authority
ES
Spain
Prior art keywords
day
seladelpar
compound
pruritus
cholestatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21201888T
Other languages
English (en)
Spanish (es)
Inventor
Pol Boudes
Charles A Mcwherter
Alexandra S Steinberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CymaBay Therapeutics Inc
Original Assignee
CymaBay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CymaBay Therapeutics Inc filed Critical CymaBay Therapeutics Inc
Application granted granted Critical
Publication of ES3012120T3 publication Critical patent/ES3012120T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Pyrane Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Ladders (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
ES21201888T 2017-09-26 2018-09-24 Treatment of cholestatic pruritus with seladelpar Active ES3012120T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762563395P 2017-09-26 2017-09-26

Publications (1)

Publication Number Publication Date
ES3012120T3 true ES3012120T3 (en) 2025-04-08

Family

ID=64564950

Family Applications (2)

Application Number Title Priority Date Filing Date
ES21201888T Active ES3012120T3 (en) 2017-09-26 2018-09-24 Treatment of cholestatic pruritus with seladelpar
ES18811954T Active ES2902349T3 (es) 2017-09-26 2018-09-24 Tratamiento de prurito colestásico

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES18811954T Active ES2902349T3 (es) 2017-09-26 2018-09-24 Tratamiento de prurito colestásico

Country Status (26)

Country Link
US (2) US20190105291A1 (https=)
EP (3) EP3973959B8 (https=)
JP (1) JP7023371B2 (https=)
KR (1) KR102376794B1 (https=)
CN (1) CN111132675B (https=)
AU (2) AU2018342323B2 (https=)
BR (1) BR112020005074A2 (https=)
CA (1) CA3076614C (https=)
CY (1) CY1124894T1 (https=)
DK (1) DK3973959T3 (https=)
ES (2) ES3012120T3 (https=)
FI (1) FI3973959T3 (https=)
HR (2) HRP20212010T1 (https=)
HU (2) HUE057377T2 (https=)
IL (2) IL273569B (https=)
LT (2) LT3687523T (https=)
MX (1) MX392537B (https=)
PL (2) PL3973959T3 (https=)
PT (2) PT3973959T (https=)
RS (1) RS62790B1 (https=)
SG (1) SG11202002253SA (https=)
SI (2) SI3687523T1 (https=)
SM (1) SMT202200171T1 (https=)
UA (1) UA125600C2 (https=)
WO (1) WO2019067373A1 (https=)
ZA (1) ZA202001646B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
RS57970B1 (sr) 2014-03-20 2019-01-31 Cymabay Therapeutics Inc Tretman intrahepatičkih holestatskih oboljenja
US12053445B2 (en) 2016-03-31 2024-08-06 Genfit Methods of treatment of cholestatic diseases
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
MX2022009776A (es) * 2020-02-10 2022-09-09 Genfit Tratamiento de la colangitis biliar primaria con elafibranor.
CN115884765A (zh) 2020-08-26 2023-03-31 基恩菲特公司 用于治疗原发性胆汁性胆管炎的组合物和方法
CN116490191A (zh) * 2020-10-20 2023-07-25 葛兰素史克知识产权第二有限公司 治疗胆汁淤积性瘙痒的方法
US20220241228A1 (en) 2021-02-01 2022-08-04 Cymabay Therapeutics, Inc. Treatment of cholangiopathies
JP2026509094A (ja) 2023-01-29 2026-03-17 シマベイ セラピューティクス, インコーポレーテッド 尿毒症性掻痒の治療
WO2024159051A1 (en) 2023-01-29 2024-08-02 Cymabay Therapeutics, Inc. Treatment of chronic pruritic dermatoses
WO2025250635A1 (en) * 2024-05-28 2025-12-04 Avior, Inc. Use of nalmefene hydrochloride buccal films in treating liver disease associated pruritus
US20260060948A1 (en) 2024-07-31 2026-03-05 Cymabay Therapeutics, Inc. Methods for treating liver disease
CN121023009A (zh) * 2025-10-31 2025-11-28 浙江大学医学院附属妇产科医院(浙江省妇女医院、浙江省妇女保健院) 基于唾液样本的妊娠期肝内胆汁淤积症易感基因多重pcr—ngs筛查方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
RS57970B1 (sr) 2014-03-20 2019-01-31 Cymabay Therapeutics Inc Tretman intrahepatičkih holestatskih oboljenja
JP2020533339A (ja) * 2017-09-13 2020-11-19 ノバルティス アーゲー Fxrアゴニストを含む組合せ

Also Published As

Publication number Publication date
EP3687523A1 (en) 2020-08-05
SI3687523T1 (sl) 2022-05-31
MX392537B (es) 2025-03-04
SMT202200171T1 (it) 2022-05-12
AU2021254641B2 (en) 2022-02-24
AU2018342323A1 (en) 2020-04-16
RS62790B1 (sr) 2022-02-28
CY1124894T1 (el) 2023-01-05
CN111132675A (zh) 2020-05-08
IL273569B (en) 2021-12-01
ES2902349T3 (es) 2022-03-28
EP3687523B1 (en) 2021-11-03
WO2019067373A1 (en) 2019-04-04
MX2020007273A (es) 2022-05-23
SG11202002253SA (en) 2020-04-29
IL288340B1 (en) 2023-01-01
EP3973959B1 (en) 2024-12-11
PT3687523T (pt) 2021-12-06
KR20200058458A (ko) 2020-05-27
HUE070033T2 (hu) 2025-05-28
AU2021254641A1 (en) 2021-11-18
EP3973959B8 (en) 2025-01-15
PL3687523T3 (pl) 2022-02-21
UA125600C2 (uk) 2022-04-27
PL3973959T3 (pl) 2025-03-24
JP7023371B2 (ja) 2022-02-21
US20190105291A1 (en) 2019-04-11
BR112020005074A2 (pt) 2020-09-15
CN111132675B (zh) 2023-04-25
RU2020114644A (ru) 2021-10-27
LT3687523T (lt) 2022-03-25
NZ762976A (en) 2021-11-26
LT3973959T (lt) 2025-01-10
PT3973959T (pt) 2025-01-24
SI3973959T1 (sl) 2025-03-31
IL288340B2 (en) 2023-05-01
EP4523744A3 (en) 2025-06-04
US20210283078A1 (en) 2021-09-16
IL288340A (en) 2022-01-01
IL273569A (en) 2020-05-31
DK3973959T3 (da) 2025-01-20
ZA202001646B (en) 2021-08-25
EP4523744A2 (en) 2025-03-19
HRP20250022T1 (hr) 2025-03-14
CA3076614A1 (en) 2019-04-04
CA3076614C (en) 2023-02-07
HRP20212010T1 (hr) 2022-04-01
AU2018342323B2 (en) 2021-09-23
KR102376794B1 (ko) 2022-03-18
RU2020114644A3 (https=) 2022-02-14
EP3973959A1 (en) 2022-03-30
JP2020535225A (ja) 2020-12-03
HUE057377T2 (hu) 2022-05-28
FI3973959T3 (fi) 2025-02-03

Similar Documents

Publication Publication Date Title
ES3012120T3 (en) Treatment of cholestatic pruritus with seladelpar
ES2701094T3 (es) Tratamiento de enfermedades colestáticas intrahepáticas
KR102408288B1 (ko) 간내 담즙 정체성 질환의 치료
US11224580B2 (en) Treatment of intrahepatic cholestatic diseases
RU2781281C2 (ru) Лечение холестатического зуда
HK40121699A (en) Treatment of cholestatic pruritus
HK40062783B (en) Treatment of cholestatic pruritus with seladelpar
HK40062783A (en) Treatment of cholestatic pruritus with seladelpar
HK40033446A (en) Treatment of cholestatic pruritus with seladelpar
HK40033446B (en) Treatment of cholestatic pruritus with seladelpar
NZ762976B2 (en) Treatment of cholestatic pruritus
JP7596548B2 (ja) 胆管症の治療
HK1229212B (en) Treatment of intrahepatic cholestatic diseases
HK1229212A1 (en) Treatment of intrahepatic cholestatic diseases